ClinicalTrials.gg
CompletedNCT00332852Updated Feb 23, 2017

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

A Phase 3 interventional study of Letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
655
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
23rd of 159
655 · median 95
Started
2006
with 6 others
Phase 3
41 of 162
4 open now
Registered
36th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 23rd largest by enrollment of the 159 interventional ones that give a count, is one of 7 that started in 2006, is one of 41 in phase 3, and was the 36th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast cancer.

This trial is not recruiting patients in the United States.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Postive breast cancer
  • postmenopausal
  • disease free survival
  • letrozole
  • early adjuvant treatment
  • primary hormone receptor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Compliant women with primary operable breast cancer after complete surgery and suitable for endocrine treatment
  • Nodal status negative or positive
  • Good Health status 0-2 ()
  • Estrogen- and/or progesterone-receptor positive
  • Adequate marrow, kidney and liver function

Exclusion criteria

Exclusion criteria:

  • or inflammatory breast cancer
  • Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancer or in situ cancer of the cervix. Patients with other previous cancers must have been disease-free for at least 5 years and Patients with uncontrolled, non-malignant systemic cardiovascular, kidney, and liver diseases.
  • Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery
  • Patients with primary overactive parathyroid
  • Patients with a known to zoledronic acid or other bisphosphonates.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
655 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

  • 2.5 mg/day - oraly

    Also known as: Femara, FEM345

06

What researchers measure

Primary outcomes

  1. Rate of patients without recurrence after 24 months of Letrozole treatment as assessed by radiological imaging

    Time frame: after 24 months

Secondary outcomes

  1. Disease free survival (DFS)

    Time frame: every 6 months for 24 months

  2. Quality of life as assessed by EORTC QLQ-C30 + BR23 every 3 months

    Time frame: Every 6 months

  3. Safety and tolerability with assessments incuding biochemistry, hematology, ECG, pyhsical exam and AE documentation

    Time frame: every 6 months

07

Study locations

54 sites
  • Novartis Investigative Site
    Albstadt, Germany
  • Schorndorf
    Augsburg, Germany
  • Novartis Investigative Site
    Bamberg, Germany
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Bonn, Germany
  • Novartis Investigative Site
    Bottrop, Germany
  • Novartis Investigative Site
    Braunschweig, Germany
  • Novartis Investigative site
    Celle, Germany
  • Novartis Investigative Site
    Chemnitz, Germany
  • Novartis Investigative Site
    Dortmund, Germany
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Fulda, Germany
  • Novartis Investigative Site
    Gera, Germany
  • Novartis Investigative Site
    Gütersloh, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Hameln, Germany
  • Novartis Investigative Site
    Hannover, Germany
  • Novartis Investigative Site
    Herne, Germany
  • Novartis Investigative Site
    Holzminden, Germany
  • Novartis Investigative Site
    Hoxter, Germany
  • Novartis Investigative Site
    Ilsede, Germany
  • Novartis Investigative Site
    Itzehoe, Germany
  • Novartis Investigative Site
    Jena, Germany
  • Novartis Investigative Site
    Karlsruhe, Germany
  • Novartis Investigative Site
    Kempten, Germany
  • Novartis Investigative Site
    Konigs, Germany
  • Schorndorf
    Konstanz, Germany
  • Novartis Investigative Site
    Lich, Germany
  • Novartis Investigative Site
    Lohsa/Weisskollm, Germany
  • Novartis Investigative Site
    Ludwigsburg, Germany
  • Novartis Investigative Site
    Memmingen, Germany
  • Novartis Investigative Site
    Muhlhausen, Germany
  • Novartis Investigative Site
    Munchen, Germany
  • Novartis Investigative Site
    Munster, Germany
  • Novartis Investigative Site
    Neumunster, Germany
  • Novartis Investigative Site
    Neunkirchen, Germany
  • Novartis Investigative Site
    Offenburg, Germany
  • Novartis Investigative Site
    Pforzheim, Germany
  • Novartis Investigative Site
    Rendsburg, Germany
  • Novartis Investigative Site
    Saarbrucken, Germany
  • Novartis Investigative Site
    Saarbrücken, Germany
  • Novartis Investigative Site
    Saarlouis, Germany
  • Novartis Investigative Site
    Salzgitter, Germany
  • Novartis Investigative Site
    Schorndorf, Germany
  • Novartis Investigative Site
    Schwetzingen, Germany
  • Novartis Investigative Site
    St. Wendel, Germany
  • Novartis Investigative Site
    Starnberg, Germany
  • Novartis Investigative Site
    Stuttgart, Germany
  • Novartis Investigative Site
    Tuttlingen, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Walsrode, Germany
  • Novartis Investigative Site
    Westerburg, Germany
  • Novartis Investigative Site
    Wiesbaden, Germany
  • Novartis Investigative Site
    Wolfsburg, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a primary completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2006
First posted
Jun 2, 2006
Start
Mar 2006
Primary completionActual
Jul 2010
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00332852
First posted
Jun 2, 2006
Start date
Mar 2006
Primary completion
Jul 2010
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion